September 16, 2020
From the Editor
40
9
In this September 2020 Product Launch issue of Pharm Exec, we highlight five products, all approved in 2019, and showcase what is now their early brand journey.
September 14, 2020
Features
40
9
Beyond necessity and nice-to-have, embracing real-world evidence as a true strategic differentiator.
September 14, 2020
Features
40
9
Turning to a next-gen psoriasis treatment to help drive future fortunes.
September 14, 2020
Features
40
9
While COVID-19 has shifted some of the rules, research reveals that practice changes were already afoot for market newcomers.
September 14, 2020
Features
40
9
Uncovering fish oil derivative’s benefit for heart health.
September 14, 2020
Features
40
9
New hope accompanies overdue recognition in sickle cell disease fight.
September 14, 2020
Features
40
9
Addressing the need for fast-acting therapy in treatment-resistant depression.
September 14, 2020
Features
40
9
The world’s most expensive drug put in context.
September 11, 2020
Columns
40
9
The key factors behind the sector’s strong surge in new equity fundraisings.
September 11, 2020
Columns
40
9
Orphan drug incentives set to remain in place in Europe.
September 11, 2020
Columns
40
9
Tasked with setting up framework for essential medicine program.
September 11, 2020
Features
40
9
How adoption of the key account management (KAM) model can help drive pharma’s agility in reaching and influencing a more diverse set of healthcare customers and decision-makers.
September 11, 2020
Columns
40
9
As we wait for a COVID-19 vaccine, pharma is looking to blockchain technology to prepare for the major supply-chain obstacles to come.
September 11, 2020
Columns
40
9
Creating behavioral change in the pharma workplace.
September 11, 2020
Features
40
9
Amid pandemic, rely on the fundamentals.
September 11, 2020
Features
40
9
A glimpse inside the latest turn in Liz Barrett’s influential journey as an oncology executive—this time leaving the confines of big pharma to tackle the innovation void in treating urologic cancers.
September 11, 2020
Columns
40
9
ESG objectives are integral to long-term biopharma strategy.
September 11, 2020
Features
40
9
Assessing COVID-19’s wide and varied impact on pharma and biotech business in the first half of the year, and how it shapes market prospects ahead.
September 10, 2020
Issue PDF
40
9
Click the title above for a link to open the Pharmaceutical Executive September 2020 issue in an interactive PDF format.